1. Mohr DN, Offord KP, Owen RA, Melton LJ 3rd. Asymptomatic microhematuria and urologic disease. A populationbased study. JAMA 1986;256:224-229.
2. Davis R, Jones JS, Barocas DA, et al. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol 2012;188((6 Suppl):2473-2481.
3. Rai BP, Luis Dominguez Escrig J, Vale L, et al. Systematic review of the incidence of and risk factors for urothelial cancers and renal cell carcinoma among patients with haematuria. Eur Urol 2022;82:182-192.
5. Anderson J, Fawcett D, Feehally J, et al. Joint consensus statement on the initial assessment of haematuria. BAUS/RA Guidel 2008;2008:1-5.
7. Barocas DA, Boorjian SA, Alvarez RD, et al. Microhematuria: AUA/SUFU guideline. J Urol 2020;204:778-786.
8. Elias K, Svatek RS, Gupta S, Ho R, Lotan Y. High-risk patients with hematuria are not evaluated according to guideline recommendations. Cancer 2010;116:2954-2959.
11. Richards KA, Ham S, Cohn JA, Steinberg GD. Urinary tract infection-like symptom is associated with worse bladder cancer outcomes in the Medicare population: implications for sex disparities. Int J Urol 2016;23:42-47.
12. Hiatt RA, Ordoñez JD. Dipstick urinalysis screening, asymptomatic microhematuria, and subsequent urological cancers in a population-based sample. Cancer Epidemiol Biomarkers Prev 1994;3:439-443.
13. Bhatt NR, Davis NF, Nolan WJ, et al. Incidence of visible hematuria among antithrombotic agents: a systematic review of over 175,000 patients. Urology 2018;114:27-32.
14. Yu HT, Kim TH, Uhm JS, et al. Clinical significance of hematuria in atrial fibrillation with oral anticoagulation therapy. Circ J 2017;81:158-164.
18. Grossfeld GD, Litwin MS, Wolf JS, et al. Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy. Part I: definition, detection, prevalence, and etiology. Urology 2001;57:599-603.
19. Mommsen S, Aagaard J, Sell A. Presenting symptoms, treatment delay and survival in bladder cancer. Scand J Urol Nephrol 1983;17:163-167.
20. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. Int J Cancer; 2021.
22. Rink M, Crivelli JJ, Shariat SF, Chun FK, Messing EM, Soloway MS. Smoking and bladder cancer: a systematic review of risk and outcomes. Eur Urol Focus 2015;1:17-27.
23. Yoo S, Han KD, Kim KT. Bladder cancer in South Korea: analysis of trends and risk factors of bladder cancer in South Korea using a nationwide database. J Urol Oncol 2023;21:45-52.
24. Masaoka H, Matsuo K, Ito H, et al. Cigarette smoking and bladder cancer risk: an evaluation based on a systematic review of epidemiologic evidence in the Japanese population. Jpn J Clin Oncol 2016;46:273-283.
26. Sylvester RJ, Rodríguez O, Hernández V, et al. European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel. Eur Urol 2021;79:480-488.
30. Jubber I, Shariat SF, Conroy S, et al. Non-visible haematuria for the detection of bladder, upper tract, and kidney cancer: an updated systematic review and meta-analysis. Eur Urol 2020;77:583-598.
31. Chow WH, Gridley G, Fraumeni JF Jr, Järvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med 2000;343:1305-1311.
32. Yoo S, You D, Song C, et al. Declining incidence of benign lesions among small renal masses treated with surgery: effect of diagnostic tests for characterization. Urol Oncol 2018;36:362.
34. Campbell SC, Clark PE, Chang SS, Karam JA, Souter L, Uzzo RG. Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA guideline. Part I. J Urol 2021;206:199-208.
35. Abu-Ghanem Y, Fernández-Pello S, Bex A, et al. Limitations of available studies prevent reliable comparison between tumour ablation and partial nephrectomy for patients with localised renal masses: a systematic review from the European Association of Urology Renal Cell Cancer guideline panel. Eur Urol Oncol 2020;3:433-452.
36. Cheaib JG, Patel HD, Johnson MH, et al. Stage-specific conditional survival in renal cell carcinoma after nephrectomy. Urol Oncol 2020;38:6.
37. Lwin AA, Hsu CH, Chipollini J. Urothelial carcinoma of the renal pelvis and ureter: does location make a difference? Clin Genitourin Cancer 2020;18:45-49.
38. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. Eur Urol 2021;79:62-79.
39. Park J, Ha SH, Min GE, et al. The protective role of renal parenchyma as a barrier to local tumor spread of upper tract transitional cell carcinoma and its impact on patient survival. J Urol 2009;182:894-899.
40. Seisen T, Granger B, Colin P, et al. A systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma. Eur Urol 2015;67:1122-1133.
42. Chlapoutakis K, Theocharopoulos N, Yarmenitis S, Damilakis J. Performance of computed tomographic urography in diagnosis of upper urinary tract urothelial carcinoma, in patients presenting with hematuria: systematic review and meta-analysis. Eur J Radiol 2010;73:334-338.
44. Tsivian A, Tsivian M, Stanevsky Y, Tavdy E, Sidi AA. Routine diagnostic ureteroscopy for suspected upper tract transitionalcell carcinoma. J Endourol 2014;28:922-925.
45. Yoo S, You D, Song C, et al. Risk of intravesical recurrence after ureteroscopic biopsy for upper tract urothelial carcinoma: does the location matter? J Endourol 2017;31:259-265.
46. Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009;115:1224-1233.